Physician profile
Ivan Tseng
NPI 1083094635
$1,378.04
in general payments reported to CMS, 2019-2025
16 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.11 · 2022: $227 · 2023: $341 · 2024: $429 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.57 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $257.82 | 2022-2024 | Photrexa |
| Abbvie INC. | $240.97 | 2022-2025 | Durysta |
| Harrow Eye, LLC | $188.33 | 2024-2025 | Vevye |
| Coopervision INC. | $120.19 | 2022-2025 | Myday Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $111.44 | 2022-2025 | Rocklatan, Clareon, Tryptyr |
| Oyster Point Pharma, INC. | $109.97 | 2023-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $84.13 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $71.96 | 2023-2025 | Vyzulta, Xiidra, Miebo |
| Novartis Pharmaceuticals Corporation | $59.04 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $25.25 | 2023 | Tecnis Iol |
| Sight Sciences, INC. | $21.86 | 2025 | Tearcare System |
| Biotissue Holdings INC. | $20.77 | 2022 | |
| Thea Pharma INC. | $18.38 | 2023 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $16.88 | 2023 | Flarex |
| Apellis Pharmaceuticals, INC. | $16.39 | 2025 | Syfovre |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $14.66 | 2025 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Tseng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.